Innovative Glucagon-like Peptide 1 Receptor Agonists: Exploring the Therapeutic Potential of Specific Modified Monomer, Dimer, and Tetramer in Type 2 Diabetes Treatment
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Yan Du und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratories & Pathology, Guangdong Provincial Corps Hospital of Chinese People's Armed Police Forces, Guangzhou 510507, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptide 1. Die Arbeit nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Key Area Project of General Universities in Guangdong Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Modified glucagon-like peptide 1 (GLP-1) plays a crucial role in type 2 diabetes (T2D) treatment. The comparative hypoglycemic effect among fatty-acid-modified GLP-1 monomer G20, dimer 2G21, and tetramer 4G18 was evaluated in T2D mice. The polymers exhibited an opposite solubility with their monomers. After single administration, the oral glucose tolerance test results showed that the monomers, dimer, or tetramer, respectively, had 3-9, 21, or 35 days of hypoglycemic effect or plasma stability. G20 had a moderate hypoglycemic effect, and its peak effect occurred in week 1 as semaglutide. 2G21 showed a strongly hypoglycemic effect in week 1-10, and its peak effect occurred in week 4. 4G18 had a weak effect initially but rapidly strengthened in weeks 6-10 and reached its peak effect in week 10. After the 10 week interference, compared to the model control group, G20 (-19.7 or -4.3%), 2G21-L/M/H (-15.9/-34.3/-26.7% or -6.0/-34.4/-36.2%), and 4G18-L/M/H groups (-44.3/-49.8/-53.8% or -40.9/-50.6/-50.8%) significantly exhibited hypoglycemic effects in postprandial glucose or fasting plasma glucose changes. Insulin altered +4.1% (G20), -9.6/+10.0/+36.5% (2G21-L/M/H), and +38.5/+28.7/+84.8% (4G18-L/M/H). HbA1c or body weight reduced -11.9 or -0.18% (G20), -5.2/-15.2/-19.1% or +0.5/-4.7/-1.2% (2G21-L/M/H), and -5.8/-4.8/-5.4% or -2.9/-2.1/-3.1% (4G18-L/M/H), showing a dose-dependent reduction in 2G21, whereas the 4G18 had lower variations. 2G21 induced a hypoglycemic effect and diet stress, whereas 4G18 only did a hypoglycemic effect and showed a stronger protection to the model organs and more improvement in the nerve muscle than G20 or 2G21. The endogenous insulin release depends not only on the GLP-1 peptide dose but also on the peptide chain in the polymer skeleton.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratories & Pathology, Guangdong Provincial Corps Hospital of Chinese People's Armed Police Forces, Guangzhou 510507, China.
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Department of Biochemistry and Molecular Biology, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Translational Medicine Center, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
- Department of Pathology, Sanya People's Hospital, Sanya, Hainan Province 572000, China.
- Department of Clinical Laboratories, Luopu Community Health Service Center, Guangzhou 511431, China.
ORCID-Profile: Song-Shan Tang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Key Area Project of General Universities in Guangdong Province
- YD private finance
- Medical Grant of Guangdong Province
- Shenzhen Nafe Biopharmaceutical Company Ltd
Zitieren
APA
Du, Y., Liu, T., Li, H. L., Luo, Q., Guo, X. Y., Wang, J. Y., Wang, X. R., Zhou, Y. M., Pan, Y. W., Yu, L. C., Tan, H. M., Hu, K. S., & Tang, S. S. (2025). Innovative Glucagon-like Peptide 1 Receptor Agonists: Exploring the Therapeutic Potential of Specific Modified Monomer, Dimer, and Tetramer in Type 2 Diabetes Treatment. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00261
Vancouver
Du Y, Liu T, Li HL, Luo Q, Guo XY, Wang JY, et al. Innovative Glucagon-like Peptide 1 Receptor Agonists: Exploring the Therapeutic Potential of Specific Modified Monomer, Dimer, and Tetramer in Type 2 Diabetes Treatment. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00261
BibTeX
@article{Du2025,
author = {Du, Yan and Liu, Tao and Li, Hua-Lin and Luo, Qun and Guo, Xiao-Yuan and Wang, Jian-Yun and Wang, Xin-Rui and Zhou, Ya-Man and Pan, Ya-Wen and Yu, Li-Cheng and Tan, Hong-Mei and Hu, Ke-Sheng and Tang, Song-Shan},
title = {Innovative Glucagon-like Peptide 1 Receptor Agonists: Exploring the Therapeutic Potential of Specific Modified Monomer, Dimer, and Tetramer in Type 2 Diabetes Treatment},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00261}
}
EUVIMED